유전자 편집 완벽 가이드.
★
메뉴
홈 배우기 뉴스 아틀라스에 질문하기
둘러보기 기술들 질환 치료법들 임상시험 기업 과학자들 유전자 연구 기관
의학을 넘어서 농업 윤리 투자 세계 지도
배우기 & 도구 여기서 시작하세요 용어집 A–Z 기술 비교 타임라인 목록 & 순위 AI 에이전트 ★ 저장됨 API
소개 소개 방법론 데이터 출처 편집 방침 문의 면책 조항

🧭 안내 보기
유전학이 처음이신가요? 둘러보시는 동안 모든 용어를 쉬운 말로 설명해 드립니다. 도움말이 내장된 동일한 페이지입니다.

⚡ 전문가 견해
생물학은 이미 알고 계시죠. 내용만 — 깔끔하고 간결하게, 추가 설명 없이. 기본 보기입니다.

인터페이스 언어
라이트 모드

유전자 편집 혁명 지도

CRISPR Atlas

유전 의학의 미래를 만들어가는 기술, 치료법, 질병, 과학자, 기업, 임상시험, 그리고 새로운 발견들을 살펴보세요.

17 기술 19 질환 15 treatments 14 clinical trials 17 companies 19 genes 교육용 참고자료 · 연구 목적만 · 의학적 조언 아님
You are in Guided View. Terms are explained as you go, and every page opens with a plain-language summary before the technical detail. Switch back to Expert View from the menu at any time.

유전자 편집 탐색하기

과학자들이 유전 물질을 변형하는 일곱 가지 방법입니다. 각 페이지는 쉬운 설명으로 시작해, 원하는 만큼 깊이 파고들 수 있습니다.

전체 기술 →
CRISPR-Cas9A protein that can be programmed with a short RNA guide to find one specific sequence in a genome and cut it. Base EditingChemically converts one DNA letter into another at a chosen position, without cutting both strands of the double helix. Prime EditingWrites a new stretch of DNA sequence directly into a chosen site, using a guide that carries the replacement text with it. CRISPR-Cas12A family of CRISPR nucleases that cut DNA leaving staggered ends, use a different sequence requirement from Cas9, and can be smaller. CRISPR-Cas13Targets RNA rather than DNA, so it can silence a gene's message without touching the genome itself. Cas14 and miniature Cas systemsUnusually small CRISPR nucleases — roughly a third the size of Cas9 — discovered in archaea and bacteriophages. RNA EditingChanges letters in the RNA message rather than in the DNA, so the effect is real but temporary and the genome is untouched. 나란히 비교해보기정밀도, 절단 방식, 탑재 용량 크기, 전달 방법, 성숙도, 위험성

표적 질환

각 질환 페이지에는 유전자 편집이 승인된 치료법인지, 임상시험 중인지, 아직 실험실 단계에만 머물러 있는지가 명확하게 나와 있습니다.

전체 질환 →
Sickle Cell DiseaseBlood disorders Beta ThalassemiaBlood disorders ATTR AmyloidosisMetabolic disease Hereditary AngioedemaRare genetic disease High Cholesterol and Familial HypercholesterolemiaCardiovascular disease CancerCancer Leukemia and LymphomaCancer HIVInfectious disease Duchenne Muscular DystrophyMuscular disease Cystic FibrosisRare genetic disease

치료법들

모든 항목에 규제 현황이 명시된 약품 목록입니다.

Casgevy (exagamglogene autotemcel)The first CRISPR-based medicine approved anywhere in the world — a one-time therapy made from a patient's own edited blood stem cells. Approved Lyfgenia (lovotibeglogene autotemcel)Approved on the same day as Casgevy for sickle cell disease — but a gene-addition therapy, not gene editing, which makes the pair a useful comparison. Approved Zynteglo (betibeglogene autotemcel)An approved gene-addition therapy for transfusion-dependent beta thalassemia — the non-editing alternative to Casgevy in the same disease. Approved Nexiguran ziclumeran (nex-z)The first CRISPR therapy ever administered into a human bloodstream — a single infusion intended to switch off the TTR gene in the liver for good. Phase III Lonvoguran ziclumeran (lonvo-z)The first in vivo gene-editing therapy to report a positive Phase 3 result — a single infusion intended to stop hereditary angioedema attacks permanently. Phase III Risto-cel (BEAM-101)A base-editing therapy for sickle cell disease that mimics a naturally protective genetic variant, with a licence application signalled for as early as the end of 2026. Phase III

아틀라스에 등재된 승인된 유전자 편집 의약품: Casgevy (exagamglogene autotemcel) · Lyfgenia (lovotibeglogene autotemcel) · Zynteglo (betibeglogene autotemcel)

전체 치료법 →

임상시험

근거가 실제로 만들어지는 곳.

4모집 중
2진행 중 (모집 마감)
7완료
CLIMB SCD-121 — the trial that led to the first CRISPR medicine approvalSickle cell disease · NCT03745287 Completed CLIMB THAL-111 — the beta thalassemia trial behind the Casgevy approvalBeta thalassemia · NCT03655678 Completed MAGNITUDE — Phase 3 in vivo CRISPR for ATTR cardiomyopathyATTR amyloidosis · NCT06128629 Active, not recruiting MAGNITUDE-2 — Phase 3 in vivo CRISPR for ATTR polyneuropathyATTR amyloidosis · NCT06672237 Paused HAELO — the first positive Phase 3 result for in vivo gene editingHereditary angioedema · NCT06634420 Completed BEACON — base editing for sickle cell diseaseSickle cell disease · NCT05456880 Active, not recruiting

임상시험 데이터베이스 검색 →

알아두면 좋은 기업

누가 무엇을 만들고 있는지, 그리고 각 프로그램이 얼마나 진행되었는지.

전체 기업 →

CRSP · Zug, Switzerland

CRISPR Therapeutics

Co-founded by Emmanuelle Charpentier, and the company behind the first approved CRISPR…

NTLA · Cambridge, Massachusetts

Intellia Therapeutics

Co-founded by Jennifer Doudna, and the company that first delivered CRISPR into a human…

BEAM · Cambridge, Massachusetts

Beam Therapeutics

Founded by David Liu and colleagues to commercialise base editing — precision changes to…

EDIT · Cambridge, Massachusetts

Editas Medicine

One of the first CRISPR companies, which discontinued its cell-therapy and eye programmes…

PRME · Cambridge, Massachusetts

Prime Medicine

Founded to commercialise prime editing, and the company behind the first published…

비공개 · Boston, Massachusetts

Verve Therapeutics

Built to turn heart disease into a one-time treatment, and acquired by Eli Lilly in 2025…

CRBU · Berkeley, California

Caribou Biosciences

Co-founded by Jennifer Doudna, using hybrid RNA-DNA guides intended to make editing…

SANA · Seattle, Washington

Sana Biotechnology

Engineering transplanted cells to be invisible to the immune system, so they can be given…

이 분야를 바꾼 과학자들

각 사람이 실제로 기여한 내용 — 이 분야에서 공로 인정은 논쟁 중이며, 저희는 해당 내용을 명시합니다.

전체 과학자 →
Jennifer DoudnaStructural biochemist who, with Emmanuelle Charpentier, showed that Cas9 could be programmed with a single guide RNA to cut chosen DNA — and shared the 2020 Nobel Prize in Chemistry for it. Emmanuelle CharpentierMicrobiologist who discovered tracrRNA, the missing component of the CRISPR-Cas9 system, and shared the 2020 Nobel Prize in Chemistry with Jennifer Doudna. Feng ZhangBioengineer who led one of the first demonstrations of CRISPR genome editing in human cells and discovered several new CRISPR systems including Cas12a and Cas13. David LiuChemical biologist whose laboratory invented base editing and prime editing — the two techniques that changed gene editing from cutting to writing. George ChurchGeneticist whose laboratory independently demonstrated CRISPR editing in human cells in 2013, and a founder of an unusually large number of genomics companies. Virginijus ŠikšnysLithuanian biochemist who independently showed that Cas9 could be programmed to cut DNA, publishing in 2012 — and whose contribution is often omitted from popular accounts.

최신 유전자 편집 뉴스

실명 출판사의 실제 기사들입니다. 모든 헤드라인은 원문으로 연결되며, 저희는 기사를 재작성하거나 재게재하지 않습니다.

전체 뉴스 →
Embedding Regulatory Strategy in Cell and Gene Therapy Development In this GEN webinar, experts from Rose BioSolutions, a CDMO and Cell Solutions organization formed from Charles River Laboratories’ businesses, will… GEN — Genetic Engineering News FDA 11h ago↗ Exclusive: Third death revealed in China's popular but opaque trials A patient with an autoimmune disease has died after receiving an experimental genetic medicine from a biotech startup in China, Endpoints News has… Endpoints News Treatments 15h ago↗ Comparing traditional and NGS-based screening strategies for thalassemia in a high-prevalence Hakka population: a population-based study Nature Genetics Research 1d ago↗ The Microbiome Field Enters Its Next Chapter New analytical tools and microbiome-based therapies are pushing the field beyond early hype toward clinical and scientific progress. The post The… GEN — Genetic Engineering News Companies 1d ago↗ Rewriting Disease: Oligonucleotides Take Aim at the Untreatable How synthetic DNA and RNA are becoming the discovery engines behind a new generation of precision therapies. The post Rewriting Disease: Oligonucleotides… GEN — Genetic Engineering News Companies 1d ago↗ Pharma Races to Scale AI as Billions Flow into Drug Discovery Investors unpack what it takes to succeed in an increasingly crowded AI biology ecosystem. The post Pharma Races to Scale AI as Billions Flow into Drug… GEN — Genetic Engineering News Treatments 1d ago↗ Animals have been eating nature’s original bioplastic for millions of years Nature invented biodegradable plastic long before humans did—and animals may have been feeding on it for hundreds of millions of years. Researchers… Science Daily Agriculture 2d ago↗ Cloning could be used to save species—or make human “organ sacks” This week I spoke to scientists who have found a way to turn male mouse embryos female. They’ve developed a CRISPR-based approach to essentially cut out… MIT Technology Review Ethics 4d ago↗

CRISPR 설명

맨 처음부터 시작해 보세요. 생물학 배경 지식이 없어도 됩니다.

학습 시작하기 →

Start here

What is DNA?

DNA is a long chemical chain that stores the instructions for building and running a living thing, written in…

Start here

What is a gene?

A gene is a stretch of DNA that carries the instructions for making one particular thing the cell needs —…

Start here

What is a chromosome?

A chromosome is one very long DNA molecule packaged with proteins; humans normally have 46, in 23 pairs.

Start here

What is a genome?

A genome is the complete set of genetic instructions in an organism — every chromosome, every gene, and…

Start here

What is RNA?

RNA is DNA's working copy — a temporary, single-stranded version the cell makes when it needs to use a gene.

Start here

What is a mutation?

A mutation is a change in DNA sequence. Most do nothing, some cause disease, and a few are beneficial.

숫자로 보는 유전자 편집

Atlas 데이터베이스의 실시간 집계 수치입니다 — 이 숫자는 저희가 보유한 기록의 수이며, 해당 분야의 전체 규모를 추정한 것이 아닙니다.

0Clinical trials tracked아틀라스 레코드
0승인된 유전자 편집 치료제FDA 및/또는 EMA 승인
0Diseases covered아틀라스 레코드
0기업아틀라스 레코드
0과학자들아틀라스 레코드
0유전자아틀라스 레코드
0기술들아틀라스 레코드
0Connections between records지식 그래프 엣지

수치는 페이지를 불러올 때마다 새로 고침됩니다. '승인'은 국가 의약품 규제 기관이 하나 이상의 제품을 허가했음을 의미하며, 해당 치료제가 특정인에게 제공되거나 적합하다는 뜻은 아닙니다.

아틀라스에 질문하기 질문을 쉬운 말로 입력하세요. 답변은 이 사이트의 출처가 명시된 자체 레코드만을 바탕으로 구성되며, 사용된 페이지로 링크됩니다. 유전자 편집의 역사 DNA 구조의 발견부터 최초로 승인된 CRISPR 치료제까지 — 우리가 여기까지 오게 된 사건들을 돌아봅니다.
농업작물·가축과 나라마다 다른 규정 윤리양측의 주장을 함께 살펴봅니다 투자이 산업의 자금 조달 방식 — 정보 제공 목적이며, 투자 조언이 아닙니다 세계 지도유전자 편집이 일어나는 곳
더 읽기 전에 CRISPR Atlas는 교육용 참고 자료입니다. 의학적 조언을 제공하지 않으며, 실험적 치료에 관한 정보는 해당 치료의 안전성이나 유효성을 입증하는 근거가 아닙니다. 임상시험 및 규제 현황은 자주 변경됩니다. 본인 또는 가족의 건강과 관련한 결정이 필요한 경우, 반드시 자격을 갖춘 의료 전문가와 상담하세요. 전체 면책 조항 읽기 →